Decentralizing trials puts diversity at the center of clinical research
October 27, 2021

At Curebase, we are on a mission to ensure every patient can participate in cutting-edge medical research. We believe that including patients with varying backgrounds, experiences, and identities in clinical trials is essential for advancing healthcare. 


Our end-to-end eClinical suite addresses healthcare disparities across race, gender, and ethnicity by increasing equitable access and broadening representation of clinical trial participants while collecting quality real-world data. 


Lack of diversity in traditional clinical trials

Underrepresentation in clinical trials presents serious challenges to public health. 


According to the U.S. Census Bureau, Non-Hispanic Whites represent 60.1% of the U.S. population, Hispanic/Latinos represent 18.5%, and Black/African Americans represent 13.4%. Yet, according to the FDA 2020 Drug Trial Snapshots, on average, Non-Hispanic Whites comprise 75% of traditional trial participants, while Hispanic/Latinos comprise only 11% and Black/African Americans comprise only 8% of participants.


Recent guidance by the FDA emphasizes the importance of trial participants accurately reflecting the real-world use population. Otherwise, any conclusions may portray a skewed public health message that can further healthcare inequities. The Curebase approach leads to greater diversity in clinical trial participation by going local. Across our partnerships, our clinical trial make-up has had up to 50% more Non-White participation, including up to 67% more Black/African American participation. This is because decentralizing clinical trials addresses major obstacles to equity such as geographic location and distrust of the healthcare system. 

Circumventing the geography of healthcare through virtual trial sites

Since most traditional clinical trials are run at hospitals or universities, only people with the ability to get to the facility can participate. Most trials also involve frequent visits to the site. This requires participants to afford numerous trips on private or public transportation or live within walking distance. Obviously, this prevents many patients from participating and providing valuable data.


Incorporating virtual clinical trial sites allows the number of participants to grow exponentially. Patients across the globe can contribute to the same study without leaving their homes or travelling further than their doctor’s offices. And, researchers can gain key insight about how different lifestyles and environments influence health and medication effectiveness.


Building patient-provider relationships

As we have seen quite clearly with the rollout of the Covid-19 vaccine, many people are wary of the American healthcare system. The Tuskegee Study, for instance, is one of many historic abuses of minority groups causing ongoing generational trauma. To overcome this systemic issue, people need to trust the clinicians collecting their data and developing their treatment plans.


Our software is designed to help providers focus on building those patient relationships. With Curebase, physicians become researchers just by treating the patients they see every day. Not only does the physician-centric model encourage diversity in trial participants but it also provides opportunities for patients who might not otherwise hear about clinical trials.


Represent the underrepresented with us

While underrepresentation in clinical trials continues to be an issue, there is a general consensus among the life sciences community that we need a transformation. But how do we make sustainable and meaningful change? At Curebase, we recognize that decentralized clinical trials are the future of R&D. Every day, we are innovating and improving access for physicians, patients, and researchers. 


Learn more about how our software solutions can help your organization put people at the forefront of research!

Want to subscribe to our blog?
  • Invisible 1
  • Invisible 2
  • Invisible 3

The Curebase Blog

Decentralizing trials puts diversity at the center of clinical research

October 27, 2021

Curebase is increasing diversity in clinical research by engaging more patients in real-world data collection

At Curebase, we are on a mission to ensure every patient can participate in cutting-edge medical research. We believe that including patients with varying backgrounds, experiences, and identities in clinical trials is essential for advancing healthcare. 


Our end-to-end eClinical suite addresses healthcare disparities across race, gender, and ethnicity by increasing equitable access and broadening representation of clinical trial participants while collecting quality real-world data. 


Lack of diversity in traditional clinical trials

Underrepresentation in clinical trials presents serious challenges to public health. 


According to the U.S. Census Bureau, Non-Hispanic Whites represent 60.1% of the U.S. population, Hispanic/Latinos represent 18.5%, and Black/African Americans represent 13.4%. Yet, according to the FDA 2020 Drug Trial Snapshots, on average, Non-Hispanic Whites comprise 75% of traditional trial participants, while Hispanic/Latinos comprise only 11% and Black/African Americans comprise only 8% of participants.


Recent guidance by the FDA emphasizes the importance of trial participants accurately reflecting the real-world use population. Otherwise, any conclusions may portray a skewed public health message that can further healthcare inequities. The Curebase approach leads to greater diversity in clinical trial participation by going local. Across our partnerships, our clinical trial make-up has had up to 50% more Non-White participation, including up to 67% more Black/African American participation. This is because decentralizing clinical trials addresses major obstacles to equity such as geographic location and distrust of the healthcare system. 

Circumventing the geography of healthcare through virtual trial sites

Since most traditional clinical trials are run at hospitals or universities, only people with the ability to get to the facility can participate. Most trials also involve frequent visits to the site. This requires participants to afford numerous trips on private or public transportation or live within walking distance. Obviously, this prevents many patients from participating and providing valuable data.


Incorporating virtual clinical trial sites allows the number of participants to grow exponentially. Patients across the globe can contribute to the same study without leaving their homes or travelling further than their doctor’s offices. And, researchers can gain key insight about how different lifestyles and environments influence health and medication effectiveness.


Building patient-provider relationships

As we have seen quite clearly with the rollout of the Covid-19 vaccine, many people are wary of the American healthcare system. The Tuskegee Study, for instance, is one of many historic abuses of minority groups causing ongoing generational trauma. To overcome this systemic issue, people need to trust the clinicians collecting their data and developing their treatment plans.


Our software is designed to help providers focus on building those patient relationships. With Curebase, physicians become researchers just by treating the patients they see every day. Not only does the physician-centric model encourage diversity in trial participants but it also provides opportunities for patients who might not otherwise hear about clinical trials.


Represent the underrepresented with us

While underrepresentation in clinical trials continues to be an issue, there is a general consensus among the life sciences community that we need a transformation. But how do we make sustainable and meaningful change? At Curebase, we recognize that decentralized clinical trials are the future of R&D. Every day, we are innovating and improving access for physicians, patients, and researchers. 


Learn more about how our software solutions can help your organization put people at the forefront of research!

More articles from out blog:
Curebase welcomes
Adam Samson as director of clinical operations
June 18, 2020

At Curebase we are rapidly expanding and preparing for the wave of decentralization in clinical trials that we intend to lead. To that end we have recently hired a Director of Clinical Operations, Adam Samson...

Read more
Movember: Make It About Access
November 9, 2021

Jane Myles, VP of Clinical Trial Innovation at Curebase, highlights how decentralizing clinical trials can improve access to medical care and equity in men's health.

Read more
Decentralizing trials puts diversity at the center of clinical research
October 27, 2021

Curebase is increasing diversity in clinical research by engaging more patients in real-world data collection

Read more
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States